Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Merck & Co. 16.607, Sanofi 13.284.
Merck & Co. vs Sanofi Net Worth and Market Cap
Merck & Co. (MRK) and Sanofi (SNY) are peers in Vaccines. Merck & Co. reported revenue of $16.6B as of Q2 2026, compared with $13.3B for Sanofi. Merck & Co. leads on revenue.
Merck & Co.'s gross margin is 73.5% versus 75.5% for Sanofi. Merck & Co.'s net margin is -8.0% versus 2.8% for Sanofi.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Sanofi +14.6%, Merck & Co. +5.1%.
- Sanofi made an operating profit in its latest quarter (19.4% margin); Merck & Co. made an operating loss (-4.1%).
- Merck & Co.'s KPIs on Sterling include Merck Animal Health Livestock vs Companion Animal (Quarterly) and Merck Gardasil China Sales as Printed.
- Sanofi's KPIs on Sterling include Beyfortus Net Sales (Quarterly) and Dupixent Net Sales by Region (Quarterly).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., Sanofi.| Metric | Merck & Co. | Sanofi |
|---|---|---|
| Market Cap | - | - |
| Revenue | $16.61B | $13.28B |
| Cost of Revenue | $4.39B | $3.26B |
| Gross Profit | $12.21B | $10.03B |
| Operating Income | $-683.00M | $2.58B |
| Net Income | $-1.33B | $370.00M |
| R&D Expense | $9.74B | $2.41B |
| Earnings Per Share | -$0.54 | $0.15 |
| Gross Margin | 73.5% | 75.5% |
| Operating Margin | -4.1% | 19.4% |
| Net Profit Margin | -8.0% | 2.8% |
| Free Cash Flow | $4.48B | $4.22B |
| Cumulative Free Cash Flow | $249.70B | $51.81B |
| Operating Cash Flow | $5.37B | $5.85B |
| Cash & Equivalents | $6.85B | $6.86B |